TM 29

Drug Profile

TM 29

Alternative Names: TCAR monoclonal TM 29

Latest Information Update: 10 Aug 2000

Price : $50

At a glance

  • Originator AVANT Immunotherapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Cancer; Crohn's disease

Most Recent Events

  • 10 Aug 2000 Discontinued-Preclinical for Cancer in USA (Unknown route)
  • 10 Aug 2000 Discontinued-Preclinical for Cancer in Sweden (Unknown route)
  • 10 Aug 2000 Discontinued-Preclinical for Autoimmune disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top